264 related articles for article (PubMed ID: 23640944)
1. Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis.
Bielecki M; Kowal K; Lapinska A; Chyczewski L; Kowal-Bielecka O
Adv Med Sci; 2013; 58(1):126-33. PubMed ID: 23640944
[TBL] [Abstract][Full Text] [Related]
2. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
Kowal-Bielecka O; Bielecki M; Guiducci S; Trzcinska-Butkiewicz B; Michalska-Jakubus M; Matucci-Cerinic M; Brzosko M; Krasowska D; Chyczewski L; Kowal K
Arthritis Res Ther; 2013; 15(3):R69. PubMed ID: 23800379
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of soluble CD163 in patients with systemic sclerosis.
Nakayama W; Jinnin M; Makino K; Kajihara I; Makino T; Fukushima S; Inoue Y; Ihn H
Rheumatol Int; 2012 Feb; 32(2):403-7. PubMed ID: 21120485
[TBL] [Abstract][Full Text] [Related]
4. Increased serum levels of soluble CD163 in patients with scleroderma.
Shimizu K; Ogawa F; Yoshizaki A; Akiyama Y; Kuwatsuka Y; Okazaki S; Tomita H; Takenaka M; Sato S
Clin Rheumatol; 2012 Jul; 31(7):1059-64. PubMed ID: 22453843
[TBL] [Abstract][Full Text] [Related]
5. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.
Andersen MN; Abildgaard N; Maniecki MB; Møller HJ; Andersen NF
Eur J Haematol; 2014 Jul; 93(1):41-7. PubMed ID: 24612259
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood mononuclear cells from patients with systemic sclerosis spontaneously secrete increased amounts of vascular endothelial growth factor (VEGF) already in the early stage of the disease.
Bielecki M; Kowal K; Lapinska A; Chwiesko-Minarowska S; Chyczewski L; Kowal-Bielecka O
Adv Med Sci; 2011; 56(2):255-63. PubMed ID: 21983449
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD163 as a Potential Biomarker in Systemic Sclerosis.
Frantz C; Pezet S; Avouac J; Allanore Y
Dis Markers; 2018; 2018():8509583. PubMed ID: 29805720
[TBL] [Abstract][Full Text] [Related]
9. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
Moreno JA; Dejouvencel T; Labreuche J; Smadja DM; Dussiot M; Martin-Ventura JL; Egido J; Gaussem P; Emmerich J; Michel JB; Blanco-Colio LM; Meilhac O
Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of soluble CD163 as a specific marker of macrophage/monocyte activity in sarcoidosis patients.
Tanimura H; Mizuno K; Okamoto H
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):99-105. PubMed ID: 26278688
[TBL] [Abstract][Full Text] [Related]
11. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
Axelsson J; Møller HJ; Witasp A; Qureshi AR; Carrero JJ; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Moestrup SK; Stenvinkel P
Am J Kidney Dis; 2006 Dec; 48(6):916-25. PubMed ID: 17162146
[TBL] [Abstract][Full Text] [Related]
12. Expression of soluble sCD163 in serum of psoriatic patients is modulated by Goeckerman therapy.
Kondelkova K; Krejsek J; Borska L; Fiala Z; Hamakova K; Andrys C
Allergol Immunopathol (Madr); 2013; 41(3):158-62. PubMed ID: 22765877
[TBL] [Abstract][Full Text] [Related]
13. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Vari F; Keane C; Crooks P; Nourse JP; Seymour LA; Gottlieb D; Ritchie D; Gill D; Gandhi MK
Clin Cancer Res; 2013 Feb; 19(3):731-42. PubMed ID: 23224400
[TBL] [Abstract][Full Text] [Related]
14. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
Møller HJ; Moestrup SK; Weis N; Wejse C; Nielsen H; Pedersen SS; Attermann J; Nexø E; Kronborg G
Crit Care Med; 2006 Oct; 34(10):2561-6. PubMed ID: 16915112
[TBL] [Abstract][Full Text] [Related]
15. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD163.
Møller HJ
Scand J Clin Lab Invest; 2012 Feb; 72(1):1-13. PubMed ID: 22060747
[TBL] [Abstract][Full Text] [Related]
17. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
Urbonaviciene G; Martin-Ventura JL; Lindholt JS; Urbonavicius S; Moreno JA; Egido J; Blanco-Colio LM
Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
[TBL] [Abstract][Full Text] [Related]
18. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
19. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
Greisen SR; Møller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B
Clin Exp Rheumatol; 2015; 33(4):498-502. PubMed ID: 25962601
[TBL] [Abstract][Full Text] [Related]
20. New immunological serum markers in bacteraemia: anti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis.
Gaïni S; Pedersen SS; Koldkaer OG; Pedersen C; Moestrup SK; Møller HJ
Clin Exp Immunol; 2008 Mar; 151(3):423-31. PubMed ID: 18190604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
